Deleted Tweets From Scott Gottlieb, R-D.C.

At #FDA, we’ll continue to take new steps to address youth use of nicotine, and e-cigs in particular, through additional regulatory policy measures and new enforcement actions as part of our ongoing campaign. No youth should be using any tobacco product.

RT @FDAOncology: Celebrate next Lunar New Year in a new job with #FDAOncology! Visit the FDA recruitment booth (# 2012) at #ASCO18 i… https://t.co/n1uTKWbYGd

RT @FDAOncology: #FDAOncology's @BlumenthalG to receive #ASCO18 Public Service Award today June 3 at 11:30 am in S100a https://t.co/8gms9bvwdO

RT @steveusdin1: FDA to reorganize new drug reviews. Creating a flatter organization, more engagement of FDA staff w patients, acade… https://t.co/1u3DZDtgOt

RT @CliffordHudis: Absolutely true for @ASCO and we thank you for the bold action! https://t.co/Sv0hdUyd6W QT @SGottliebFDA: Reducing addiction & death from combustible tobacco is one of my highest priorities, a goal that I know #ASCO share… https://t.co/yKvYJJYNzC)

#FDA looks forward to working collaboratively with reputable Internet sites in shared goals to crack down on online opioid sales. As for disreputable sites knowingly breaking the law, we’re stepping up enforcement actions, as early as this week https://t.

We want to make the drug review process more integrated across the discrete areas of science and regulatory expertise that are critical components of informing our overall mission to protect and promote the public health. https://t.co/H7NvzDwSIn

Our proposed modernization to FDA’s Office of New Drugs will help make sure drug review divisions are more therapeutically focused; to promote efficient review and provide greater scientific dialogue with academic partners, innovators, and patient groups.

We’ve proposed important new steps to modernize the organization and functions of FDA’s Office of New Drugs. https://t.co/H7NvzDwSIn

Our proposed modernization of FDA’s Office of New Drugs will help make sure drug review divisions have more therapeutic focus, to promote efficiency and provide greater scientific collaboration with academic partners, innovators, and patient groups. https

RT @IshwariaMD: First up. 2018 Public Service Award given to @BlumenthalG of @US_FDA - reflects on his family’s journey w cancer an… https://t.co/vWruNGcFGr

RT @SecAzar: During @POTUS's first 500 days, the @US_FDA approved over 1,000 generics to bring down the costs of prescription dr… https://t.co/OlqQsIacV7

RT @steveusdin1: Updated version of proposed OND organization, with 9 drug review offices and a new office of policy. https://t.co/2ONHeHDts2

RT @RPMReportMike: Big news today on OND Reorg. @Kate_Rawson is all over it. Press release from FDA here. https://t.co/yvByf5rsps

Our proposed modernization of FDA’s Office of New Drugs will help make sure drug review divisions have more therapeutic focus to promote efficiency and provide greater scientific collaboration with academic partners, innovators, and patient groups. https:

In 2017, #FDA approved the most generic drug applications ever, with 843 fully approved applications and 184 tentatively approved applications resulting in this total of nearly $9 billion in savings through December 2017 https://t.co/yGJuEPKDYA

In a new analysis, #FDA estimates that the total cost-savings associated with all 2017 ANDA approvals to be $11.8 billion through February 2018, with $8.8 billion in savings occurring through December 2017. https://t.co/yGJuEPKDYA

RT @FDAOncology: FDA approves first biosimilar to Neulasta https://t.co/RmWZJOtixU

RT @rschilsky: And thanks to you and your FDA colleagues for the great work you do to bring safe and effective medicines to people in need.… QT @tmprowell: Every yr at @ASCO, I think it’s not possible the mtg could be any better, & it is. That I couldn’t leave more inspi… https://t.co/jov5fQklvV)

We couldn’t let @secretarysonny leave without a small token to remind him of #FDA. From our colleagues at CFSAN, a shirt with a caption that reads “The ‘F’ in FDA” https://t.co/jsuGqfdnWI

At #FDA, we’ll continue to take new steps to address youth use of nicotine, and e-cigs in particular, through additional regulatory policy measures and new enforcement actions as part of our ongoing campaign. No youth should be using any tobacco product.

RT @FDAOncology: Celebrate next Lunar New Year in a new job with #FDAOncology! Visit the FDA recruitment booth (# 2012) at #ASCO18 i… https://t.co/n1uTKWbYGd

RT @FDAOncology: #FDAOncology's @BlumenthalG to receive #ASCO18 Public Service Award today June 3 at 11:30 am in S100a https://t.co/8gms9bvwdO

RT @steveusdin1: FDA to reorganize new drug reviews. Creating a flatter organization, more engagement of FDA staff w patients, acade… https://t.co/1u3DZDtgOt

RT @CliffordHudis: Absolutely true for @ASCO and we thank you for the bold action! https://t.co/Sv0hdUyd6W QT @SGottliebFDA: Reducing addiction & death from combustible tobacco is one of my highest priorities, a goal that I know #ASCO share… https://t.co/yKvYJJYNzC)

#FDA looks forward to working collaboratively with reputable Internet sites in shared goals to crack down on online opioid sales. As for disreputable sites knowingly breaking the law, we’re stepping up enforcement actions, as early as this week https://t.

We want to make the drug review process more integrated across the discrete areas of science and regulatory expertise that are critical components of informing our overall mission to protect and promote the public health. https://t.co/H7NvzDwSIn

Our proposed modernization to FDA’s Office of New Drugs will help make sure drug review divisions are more therapeutically focused; to promote efficient review and provide greater scientific dialogue with academic partners, innovators, and patient groups.

We’ve proposed important new steps to modernize the organization and functions of FDA’s Office of New Drugs. https://t.co/H7NvzDwSIn

Our proposed modernization of FDA’s Office of New Drugs will help make sure drug review divisions have more therapeutic focus, to promote efficiency and provide greater scientific collaboration with academic partners, innovators, and patient groups. https

RT @IshwariaMD: First up. 2018 Public Service Award given to @BlumenthalG of @US_FDA - reflects on his family’s journey w cancer an… https://t.co/vWruNGcFGr

RT @SecAzar: During @POTUS's first 500 days, the @US_FDA approved over 1,000 generics to bring down the costs of prescription dr… https://t.co/OlqQsIacV7

RT @steveusdin1: Updated version of proposed OND organization, with 9 drug review offices and a new office of policy. https://t.co/2ONHeHDts2

RT @RPMReportMike: Big news today on OND Reorg. @Kate_Rawson is all over it. Press release from FDA here. https://t.co/yvByf5rsps

Our proposed modernization of FDA’s Office of New Drugs will help make sure drug review divisions have more therapeutic focus to promote efficiency and provide greater scientific collaboration with academic partners, innovators, and patient groups. https:

In 2017, #FDA approved the most generic drug applications ever, with 843 fully approved applications and 184 tentatively approved applications resulting in this total of nearly $9 billion in savings through December 2017 https://t.co/yGJuEPKDYA

In a new analysis, #FDA estimates that the total cost-savings associated with all 2017 ANDA approvals to be $11.8 billion through February 2018, with $8.8 billion in savings occurring through December 2017. https://t.co/yGJuEPKDYA

RT @FDAOncology: FDA approves first biosimilar to Neulasta https://t.co/RmWZJOtixU

RT @rschilsky: And thanks to you and your FDA colleagues for the great work you do to bring safe and effective medicines to people in need.… QT @tmprowell: Every yr at @ASCO, I think it’s not possible the mtg could be any better, & it is. That I couldn’t leave more inspi… https://t.co/jov5fQklvV)

We couldn’t let @secretarysonny leave without a small token to remind him of #FDA. From our colleagues at CFSAN, a shirt with a caption that reads “The ‘F’ in FDA” https://t.co/jsuGqfdnWI